Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising demand for targeted therapies
3.2.1.2 Growing prevalence of cancer
3.2.1.3 Advances in biotechnology and genetic engineering
3.2.1.4 Growth in regulatory approvals
3.2.2 Industry pitfalls & challenges
3.2.2.1 Concerns related to stability in single-chain variable fragments
3.2.2.2 High development cost
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Regulatory landscape
3.6 Future market trends
3.7 Porter’s analysis
3.8 Pipeline analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Specificity, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Monoclonal antibody
5.2.1 Praxbind (Idarucizumab)
5.2.2 Ranibizumab (Lucentis)
5.2.3 Certolizumab pegol (Cimzia)
5.2.4 Iodine (I 311) metuximab/ licartin
5.2.5 Beovu (Brolucizumab-dbll)
5.2.6 Cablivi (Caplacizumab-yhdp)
5.2.7 Blinatumomab
5.3 Polyclonal antibody
5.3.1 CroFab
5.3.2 Anavip
5.3.3 Anascorp
5.3.4 Botulism antitoxin heptavalent
5.3.5 Digibind
5.3.6 DigiFab
Chapter 6 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 FAB
6.3 scFv
6.4 sdAb
6.5 Other types
Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Cancer
7.3 Immunodeficiency
7.4 Other applications
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AbbVie Inc.
9.2 Amgen
9.3 AstraZeneca
9.4 BioNTech
9.5 Bristol-Myers Squibb Company
9.6 Eli Lilly and Company
9.7 Genentech, Inc.
9.8 Johnson & Johnson
9.9 Merck & Co.
9.10 MorphoSys
9.11 Novartis AG
9.12 Pfizer Inc.
9.13 Sanofi
9.14 Takeda Pharmaceutical Company Limited
9.15 UCB Pharma
